Scarica l'app Stockscreener
14.19
5.08%
-0.76
Dopo l'orario di chiusura:
14.19
Precedente Chiudi:
$14.95
Aprire:
$14.39
Volume 24 ore:
931.68K
Relative Volume:
0.92
Capitalizzazione di mercato:
$1.01B
Reddito:
$133.62M
Utile/perdita netta:
$-177.37M
Rapporto P/E:
-4.91
EPS:
-2.89
Flusso di cassa netto:
$23.50M
1 W Prestazione:
-7.32%
1M Prestazione:
-19.74%
6M Prestazione:
+71.58%
1 anno Prestazione:
-39.44%
Intervallo 1D:
$13.94
$14.66
Intervallo di 1 settimana:
$13.77
$15.40
Portata 52W:
$6.92
$22.83
Xencor Inc Stock (XNCR) Company Profile
Nome
Xencor Inc
Settore
Industria
Telefono
626-305-5900
Indirizzo
465 N. HALSTEAD ST., PASADENA, CA
Confronta XNCR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
14.19 | 1.07B | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-10-29 | Aggiornamento | Barclays | Underweight → Overweight |
| 2025-09-17 | Ripresa | Barclays | Underweight |
| 2025-09-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-04-21 | Iniziato | William Blair | Outperform |
| 2024-12-12 | Iniziato | Wells Fargo | Overweight |
| 2024-12-02 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | Reiterato | BTIG Research | Buy |
| 2024-02-28 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | Iniziato | BofA Securities | Buy |
| 2022-12-06 | Iniziato | Cowen | Outperform |
| 2022-10-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-01-21 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-02-24 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | Iniziato | Barclays | Underweight |
| 2020-02-25 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-01-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-11-20 | Ripresa | Guggenheim | Neutral |
| 2019-08-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-08-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-04-12 | Iniziato | Guggenheim | Buy |
| 2019-03-27 | Iniziato | Berenberg | Buy |
| 2019-03-15 | Iniziato | Raymond James | Outperform |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-03-28 | Ripresa | Leerink Partners | Outperform |
| 2017-03-02 | Iniziato | Instinet | Neutral |
| 2017-03-02 | Reiterato | Wedbush | Outperform |
| 2016-10-04 | Iniziato | Piper Jaffray | Overweight |
| 2015-12-22 | Iniziato | Canaccord Genuity | Buy |
| 2015-08-05 | Reiterato | MLV & Co | Buy |
| 2015-02-12 | Reiterato | Oppenheimer | Outperform |
| 2015-01-28 | Reiterato | MLV & Co | Buy |
| 2014-07-11 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Xencor Inc Borsa (XNCR) Ultime notizie
How Xencor Inc. stock reacts to Fed rate cuts2025 Top Decliners & High Accuracy Investment Entry Signals - ulpravda.ru
Will Xencor Inc. stock benefit from upcoming earnings reports2025 Price Targets & Weekly Return Optimization Alerts - ulpravda.ru
Will Xencor Inc. stock reach Wall Street targetsQuarterly Investment Review & Community Consensus Trade Alerts - ulpravda.ru
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones - BioSpace
Xencor expects to have sufficient cash resources to fund research and development programs and operations through 2028 - MarketScreener
Xencor Expects To Have Sufficient Cash Resources To Fund Research And Development Programs And Operations Through 2028 - TradingView — Track All Markets
Xencor outlines 2026 pipeline plans for cancer and autoimmune drugs By Investing.com - Investing.com Australia
Bank of America Securities Sticks to Their Hold Rating for Xencor (XNCR) - The Globe and Mail
Xencor (NASDAQ:XNCR) Trading Down 7.1%Time to Sell? - MarketBeat
Incyte marks trial win for Xencor lymphoma drug (INCY:NASDAQ) - Seeking Alpha
Trading the Move, Not the Narrative: (XNCR) Edition - Stock Traders Daily
The Truth About Xencor Inc: Is This Quiet Biotech About To Explode? - AD HOC NEWS
Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942 (NASDAQ:XNCR) - Seeking Alpha
Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR) - Yahoo Finance
Xencor issued US patent for Xtend FC domain - MSN
Xencor (NASDAQ:XNCR) VP John Desjarlais Sells 73,367 Shares - MarketBeat
Xencor (NASDAQ:XNCR) CEO Bassil Dahiyat Sells 114,377 Shares of Stock - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Xencor SVP Desjarlais sells $1.15 million in shares By Investing.com - Investing.com Nigeria
Responsive Playbooks and the XNCR Inflection - Stock Traders Daily
Xencor SVP Desjarlais sells $1.15 million in shares - Investing.com
With Xencor Stock Sliding, Have You Assessed The Risk? - Trefis
What drives Xencor Inc stock priceMarket Liquidity Analysis & Learn the Secrets of Pro Traders - earlytimes.in
Will Xencor Inc. (XE9) stock remain on Wall Street radar2025 Biggest Moves & Entry Point Strategy Guides - Улправда
Why Xencor Inc. stock attracts global investors2025 Institutional Moves & Low Risk High Reward Ideas - Улправда
VP Desjarlais Files To Sell 73,367 Of Xencor Inc [XNCR] - TradingView — Track All Markets
Can Xencor Inc. stock sustain revenue growth2025 Market Overview & Fast Gain Stock Trading Tips - Улправда
Growth Report: Is Xencor Inc. stock ready for breakoutPortfolio Return Report & Free Safe Entry Trade Signal Reports - Улправда
Can Xencor Inc. stock resist market sell offsJuly 2025 News Drivers & AI Powered Buy/Sell Recommendations - Улправда
How supply shortages influence Xencor Inc. (XE9) stockTrade Entry Summary & Free Community Supported Trade Ideas - Улправда
Xencor Faces Structural Headwinds As Long-Term Momentum Fades - Benzinga
Squarepoint Ops LLC Acquires 351,979 Shares of Xencor, Inc. $XNCR - MarketBeat
Barclays Maintains Xencor (XNCR) Overweight Recommendation - Nasdaq
Incyte announces EU approval of Xencor-partnered lymphoma therapy - Seeking Alpha
Xencor’s New Study on XmAb657: A Potential Game-Changer for Muscle Diseases - TipRanks
Xencor Earnings Notes - Trefis
Fundamentals Check: Why Xencor Inc XE9 stock signals breakout potential - moha.gov.vn
Free cash flow per share of Xencor, Inc. – GETTEX:XE9 - TradingView — Track All Markets
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies - BioSpace
Xencor (XNCR) Is Up 7.1% After Ultomiris Royalty Patent ExtensionWhat's Changed - simplywall.st
248,706 Shares in Xencor, Inc. $XNCR Acquired by Walleye Capital LLC - MarketBeat
Xencor Granted US Patent Extension of Certain Xtend Antibodies, Expects Additional Royalty Revenue - marketscreener.com
Xencor issued U.S. patent for Xtend Fc domain - TipRanks
Xencor extends Ultomiris royalty term to 2028 with new patent - Investing.com
Xencor extends Ultomiris royalty term to 2028 with new patent By Investing.com - Investing.com South Africa
Is it possible to buy Xencor Inc(XNCR) shares at a good price now? - uspostnews.com
Xencor Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Pullback Watch: What momentum indicators show for Xencor Inc stock2025 Sector Review & Smart Swing Trading Alerts - moha.gov.vn
Is Xencor Stock Built to Withstand a Pullback? - Trefis
Xencor Inc Azioni (XNCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):